The announcement brings Calico’s total funds to $2.5 billion.
Calico and AbbVie started working together in 2014 under the agreement that Calico conducts product research and early-stage development until 2022 and Phase 2a trials through 2027, while AbbVie handles product commercialization and can chose to take on late-stage development. Together, they’ve already created more than 20 early-stage programs to combat diseases in oncology and neuroscience.
More articles on health IT:
Google sets out to organize health records
Disease detection, insurance & more — 8 ways Google may enter healthcare
How Google is using deep learning to understand EHR data and reduce readmissions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
